Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

SARS-CoV-2 vaccine development and how Brazil is contributing

Full text
Author(s):
Kanno, I, Alex ; Barbosa, Mayra M. F. [1] ; Moraes, Luana [1] ; Leite, Luciana C. C. [2]
Total Authors: 4
Affiliation:
[1] Univ Sao Paulo, Programa Posgrad Interunidades Biotecnol, Sao Paulo - Brazil
[2] Kanno, Alex, I, Inst Butantan, Lab Desenvolvimento Vacinas, Sao Paulo, SP - Brazil
Total Affiliations: 2
Document type: Review article
Source: GENETICS AND MOLECULAR BIOLOGY; v. 44, n. 1, 1 2021.
Web of Science Citations: 0
Abstract

The SARS-CoV-2 coronavirus pandemic calls for coordinated efforts by the scientific community for the development of vaccines. The most advanced strategies have focused on modifications of technologies that were already under development for other viruses, such as SARS, MERS, and even Influenza. Classic and new technologies, such as inactivated and attenuated viruses (non-replicative and replicative), DNA and mRNA vaccines, and nanoparticles containing SARS-CoV-2 antigens, are some of the strategies currently investigated. Although there is a very high expectation for the effectiveness of the most advanced vaccine candidates, there are still no established correlates of protection. Previous experience in vaccine development for other pathogens shows that differences in vaccine formulation can result in diverse immune responses and consequently, different protective properties. Therefore the importance of continuing investigations on a broad range of strategies. Expertise in vaccine development in Brazil was refocused to the new coronavirus. Impressive collaboration between institutions will support further developments until we have available a safe, effective, and economically viable vaccine. Established competence and collaborations will allow preparedness for future challenges and can also be used to address local issues as neglected infectious diseases. (AU)

FAPESP's process: 17/17218-0 - Implantation of the CRISPR-Cas9 platform in mycobacteria: investigation of ESX-1 system in the immunogenicity of BCG
Grantee:Luana Moraes
Support Opportunities: Scholarships in Brazil - Doctorate (Direct)
FAPESP's process: 17/24832-6 - Development of vaccines based on recombinant BCG: Tuberculosis, Pertussis, Pneumococcus and Schistosoma
Grantee:Luciana Cezar de Cerqueira Leite
Support Opportunities: Research Projects - Thematic Grants
FAPESP's process: 20/07547-9 - Development of a vaccine against Coronavirus SARS-CoV-2 using a new antigen presenting system
Grantee:Mayra Mara Ferrari Barbosa
Support Opportunities: Scholarships in Brazil - Post-Doctoral